References
Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38(15 suppl):6002. https://doi.org/10.1200/jco.2020.38.15_suppl.6002
Marchetti C, De Leo R, Musella A, et al. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study. Ann Surg Oncol. 2018;25(12):3701-3708. https://doi.org/10.1245/s10434-018-6700-6
Marchetti C, Rosati A, Scaletta G, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: still getting any benefit? A case-control study. Gynecol Oncol. 2019;155(3):400–405. https://doi.org/10.1016/j.ygyno.2019.09.020
Estati FL, Pirolli R, Alencar VTL, et al. Impact of BRCA1/2 mutations in the efficacy of secondary cytoreductive surgery. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-09366-w
Zang R, Zhu J, Shi T, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. J Clin Oncol. 2020;38(15 Suppl):6001. https://doi.org/10.1200/JCO.2020.38.15_suppl.6001
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Felipe Leonardo Estati, Glauco Baiocchi, and Alexandre André Balieiro Anastácio da Costa declare they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Estati, F.L., Baiocchi, G. & da Costa, A.A.B.A. ASO Author Reflections: Personalized Surgery in Recurrent Ovarian Cancer Patients. Ann Surg Oncol 28, 3646–3647 (2021). https://doi.org/10.1245/s10434-020-09368-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09368-8